VP Corporate Development
Eric Schauble has been the Vice President of Corporate Development for Colorado Therapeutics since the company was formed in 2015. Eric brings over fifteen years of experience in the biotech/ pharmaceutical and strategic consulting industries with a strong track record of success. He is also the current Vice President of Corporate Development for Colibri Heart Valve LLC, a position he has held since 2011. Prior to joining Colibri, he served in the position of Vice President, Corporate Development for Accera, Inc., a privately held biotechnology company where he successfully developed and executed the company’s strategic corporate and business development strategy. Prior to joining Accera, Eric has served in various corporate/business development and commercial roles, most notably as the Director of Market Research for Myogen, Inc. which was acquired by Gilead Sciences in 2006 for $2.5 billion. He received his B.S. in Pharmacology from the University of California at Santa Barbara and his M.S. in Biological Sciences, with an emphasis on Cardiovascular Physiology, from Stanford University.